In Brief: Cambridge Biotech
This article was originally published in The Gray Sheet
Cambridge Biotech: Agrees to sell its enteric product line to Meridian Diagnostics for $5.5 mil. cash plus a $200,000 advance payment in royalties and other considerations. Meridian's counterbid offer, which topped a previously announced $4.5 mil. agreement with Carter-Wallace ("The Gray Sheet" May 13, In Brief), was approved by the U.S. Bankruptcy Court, which is overseeing Cambridge's reorganization under Chapter 11 of the bankruptcy code. Through the reorganization plan, Cambridge is selling its diagnostic businesses to focus entirely on "therapeutic and prophylactic vaccines for infectious diseases, and immunotherapeutics for cancer," the firm says. A hearing is planned to select a "winning bid" for Cambridge's retroviral business, for which a $6.5 mil. sale agreement to bioMerieux Vitek was announced in April. Interested parties had until June 11 to submit counterbids for the retroviral business. The U.S. Bankruptcy Court will review Cambridge's overall restructuring plan at a July 15, 1996 hearing...
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.